The review meticulously examines a wide array of studies aimed at dissecting the gut-brain axis through fecal transplantation. The promise of FMT lies in its ability to recapitulate, in an animal model, the complex microecological changes observed in human psychiatric conditions. However, the authors highlight significant methodological discrepancies across studies, including variations in donor selection criteria, fecal preparation methods, recipient conditioning protocols, and outcome assessment measures.

Among the core challenges underscored is the heterogeneity of donor psychiatric diagnoses. Psychiatric illnesses, ranging from depression and anxiety to schizophrenia and bipolar disorder, exhibit diverse pathophysiological profiles that influence gut microbial composition. The review stresses the imperative need for standardized diagnostic criteria and thorough clinical characterization of donors to ensure reproducibility and interpretability of results. Without harmonized donor inclusion parameters, inter-study comparability remains severely compromised.

The fecal sample preparation itself is a pivotal factor affecting transplant efficacy. Techniques vary widely, from fresh stool homogenization to cryopreserved samples, and differences in anaerobic handling can drastically alter microbial viability. Some protocols incorporate additional processing steps such as filtering or diluting, which may selectively skew microbial communities. The review advocates for a consensus on optimal fecal preparation methods that preserve community integrity while maintaining practical feasibility for widespread application.

Recipient mice conditioning prior to FMT is another major variable impacting experimental outcomes. Pre-treatment with antibiotics to eradicate endogenous microbiota or germ-free environments are standard approaches, yet each harbors inherent limitations. Antibiotic regimens differ in spectrum, duration, and timing, influencing the niche available for donor microbiota engraftment. Germ-free conditions, though ideal experimentally, are resource-intensive and not universally accessible. The review calls for a balanced, harmonized conditioning strategy underpinned by mechanistic understanding of microbiota colonization dynamics.

Functional readouts post-transplantation are equally diverse, encompassing behavioral, neurochemical, immunological, and metabolic parameters. While many studies report alterations in anxiety-like or depressive-like behaviors in recipient mice corresponding to donor psychiatric status, the variability in behavioral testing paradigms adds complexity to cross-study comparisons. Neuroinflammatory markers and neurotransmitter profiles occasionally complement behavioral data but lack uniform measurement standards. Such fragmented reporting inhibits meta-analytical synthesis and translational extrapolation.

Delving deeper, the review discusses the emerging mechanistic insights derived from psychiatric FMT models. Altered microbial communities appear capable of modulating neuroimmune pathways, hypothalamic-pituitary-adrenal axis activity, and neurotransmission. Metabolites such as short-chain fatty acids, tryptophan derivatives, and bile acids bridge the luminal and central nervous systems, suggesting novel therapeutic targets. Deciphering these mechanisms requires integrative approaches combining multi-omics, neurophysiology, and behavioral neuroscience, an endeavor the authors urge for robust methodological frameworks.

Beyond the laboratory, the translational implications of psychiatric FMT are profound yet currently nascent. Harnessing gut microbiota modulation to ameliorate psychiatric symptoms could revolutionize treatment paradigms, offering adjunctive or alternative strategies to pharmacotherapy. However, the review prudently cautions against premature clinical extrapolation without standardized preclinical rigor. It stresses the importance of validity, reproducibility, and comprehensive mechanistic understanding before embarking on human trials.

The ethical considerations surrounding psychiatric donor stool also receive attention. Standard fecal donor screening protocols primarily focus on infectious and gastrointestinal health, but psychiatric conditions add layers of complexity regarding informed consent, privacy, and stigma. Ethical frameworks tailored to psychiatric microbiota transplantation are urgently needed to navigate these challenges responsibly.

This exhaustive review functions as both a mirror and a roadmap for the psychiatric microbiota transplantation research community. By cataloging the spectrum of current methodological practices and pinpointing critical gaps, it provides a foundation for consensus-building efforts. The authors recommend collaborative networks to develop standardized protocols encompassing donor selection, fecal processing, recipient preparation, and outcome measures, fostering comparability and accelerating progress.

In conclusion, the field of fecal microbiota transplantation from psychiatric patients to mice is rapidly evolving but remains methodologically fragmented. This systematic review from D’Onofrio et al., published in Transl Psychiatry, serves as a pivotal resource highlighting the promise and pitfalls inherent in current practices. The call for methodological standardization is not merely academic—it is essential for transforming microbiota research into clinically actionable insights that could reshape mental health care. Future research anchored in harmonized protocols holds the key to unraveling the gut-brain axis mysteries and realizing the full therapeutic potential of microbiome modulation in psychiatry.

Subject of Research:
Fecal microbiota transplantation methodologies involving psychiatric patient donors and murine recipients to explore gut-brain axis interactions in neuropsychiatric disorders.

Article Title:
Fecal microbiota transplantation from psychiatric patients to mice – systematic review of methodologies and a call for standardization.

Article References:
D’Onofrio, A.M., Gomez-Nguyen, A., Camardese, G. et al. Fecal microbiota transplantation from psychiatric patients to mice – systematic review of methodologies and a call for standardization. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03847-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03847-4

At the heart of this discovery lies the identification of a specific gene, named hsd12, within the genome of a S. aureus nasal isolate. Researchers focused on this gene after a thorough genomic search aimed at uncovering short-chain dehydrogenase/reductase (SDR) family enzymes, known for their central roles in steroid metabolism in hosts. Unlike classical virulence factors, hsd12 codes for an oxidoreductase enzyme with the ability to degrade sex hormones like estradiol and testosterone. This enzymatic function had been previously undescribed in S. aureus, thrusting the bacterium’s metabolic capabilities into a new light.

To pinpoint the impact of hsd12, scientists cloned and expressed multiple candidate hsd genes in Escherichia coli, providing a controlled system to evaluate enzymatic activity against key sex hormones. Remarkably, only the strain expressing hsd12 demonstrated potent conversion of testosterone to androstenedione and estradiol to estrone. This finding established hsd12 as a bona fide bacterial 17β-hydroxysteroid dehydrogenase (17β-HSD), an enzyme class critically involved in hormone homeostasis in mammals. The enzymatic conversion performed by hsd12 essentially inactivates active sex hormones, disrupting systemic hormone balance.

Further in vitro assays using culture filtrates from wild-type S. aureus and an isogenic hsd12 deletion mutant confirmed the functional role of this gene in hormone degradation. While wild-type bacteria efficiently converted testosterone and estradiol, the hsd12-deficient strain showed markedly diminished enzymatic activity, corroborating the gene’s pivotal role in steroid metabolism. Importantly, these modifications occurred without impairing the bacterial growth or baseline virulence factor gene expression, underscoring the targeted effect mediated by hsd12.

Moving beyond the petri dish, the study leveraged sophisticated mouse models to explore behavioral consequences arising from S. aureus nasal colonization. Female mice colonized with wild-type S. aureus expressing hsd12 displayed clear anxiety-like and depression-like behaviors in well-validated assays such as the open field test (OFT), forced swim test (FST), and tail suspension test (TST). Intriguingly, mice colonized with the hsd12 knockout strain showed no significant deviation from control groups, directly linking bacterial hormone metabolism to neuropsychiatric phenotypes.

Hormonal measurements in colonized mice provided mechanistic insights, as estradiol levels in the nasal cavity and midbrain of female mice were significantly reduced upon colonization by wild-type S. aureus. Correspondingly, male mice subjected to chronic unpredictable mild stress (CUMS) and nasal colonization also exhibited decreased testosterone levels when exposed to the wild-type strain but not the hsd12 mutant. These findings indicate that bacterial hormone degradation disrupts the local and central steroid environment, potentially impairing neuroendocrine regulation linked to mood control.

At the molecular level, analysis of midbrain gene expression revealed altered transcription of tyrosine hydroxylase (TH) and tryptophan hydroxylase 2 (TPH2), key enzymes in the biosynthesis pathways of dopamine and serotonin respectively. Both neurotransmitters are heavily implicated in the etiology of depression and anxiety. Correspondingly, biochemical assays highlighted diminished concentrations of these neurotransmitters in the midbrain of mice colonized with hsd12-expressing S. aureus, reinforcing the connection between bacterial enzymatic activity, hormone depletion, and altered neurochemical signaling.

Importantly, the study showed that bacterial colonization itself did not provoke overt inflammation or systemic illness in mice, as indicated by consistent weight, temperature, cytokine profiles, and histological assessments across groups. This suggests that the depressive phenotype arises specifically through hormone degradation rather than a generalized immune response, emphasizing a nuanced biological dialogue rather than conventional pathogen-induced sickness behavior.

The findings invite a re-examination of S. aureus, commonly considered a benign or opportunistic pathogen, as an influencer of mental health via endocrine disruption. The identification of a conserved hsd12 gene across multiple S. aureus strains indicates that sex hormone metabolism by nasal bacteria may be a widespread phenomenon with clinical ramifications. Given that S. aureus is a frequent colonizer of the human nasal vestibule, the translational implications are profound, hinting at microbial contributions to mood disorders in humans.

This study challenges the existing paradigm that treats depression as an isolated central nervous system disorder, reinforcing the concept of a microbiota-gut-brain or, more broadly, microbiota-nose-brain axis. Such axes provide a framework for how microorganisms can subtly modulate neuroendocrine circuits through biochemical means rather than overt pathogenicity. The integration of microbiology, endocrinology, and behavioral neuroscience marks a frontier in understanding the multifactorial origins of psychiatric conditions.

Moreover, therapeutic strategies derived from these insights could pivot towards targeted microbiome modulation to preserve hormonal integrity and mental health. Approaches could include the development of inhibitors to bacterial 17β-HSD enzymes, probiotics that compete with S. aureus strains harboring hsd12, or personalized nasal microbiome interventions in patients with depression. These strategies represent a novel class of psychobiotic therapies grounded in microbial endocrinology.

Notably, the model used in this work, employing nasal colonization rather than systemic infection, offers a compelling analogue for asymptomatic human carriage that still exerts functional consequences. It also underscores the importance of anatomical niche-specific interactions between microbes and host physiology. The nasal cavity, traditionally overlooked as a site of neuroendocrine influence, may play a pivotal role in shaping brain function via microbial metabolites.

The genetic precision tools employed, including the generation of an isogenic hsd12-deletion mutant, allowed the authors to attribute causality with remarkable confidence. The minimal off-target genomic effects and unaltered bacterial growth reinforce that hsd12’s hormone-degrading activity is the critical determinant of behavioral changes, rather than secondary factors linked to overall bacterial fitness or virulence.

Future research directions naturally include investigation of the prevalence and activity of hsd12-expressing S. aureus strains within human populations, particularly among individuals with mood disorders. Correlative studies and eventually interventional trials will be essential to establish the translational relevance of these findings in humans. Additionally, the interplay between microbial hormone degradation and host immune signaling merits exploration, given the complex crosstalk regulating mental states.

This pioneering work exemplifies the depth of biological complexity that arises from host-microbe interactions beyond classical infection paradigms. By revealing that nasal bacteria can enzymatically modify critical sex hormones and thereby induce behavioral alterations, it opens new vistas in our understanding of depression etiology. The hope is that such mechanistic insight will inspire innovative diagnostic and therapeutic avenues that integrate microbiology into psychiatric care.

In summary, the evidence presented revolutionizes our appreciation of S. aureus from a simple colonizer to an active participant in neuroendocrine regulation and mood modulation. The hsd12 gene serves as a molecular fulcrum for this interaction, providing a direct biochemical link between bacterial metabolism and depressive phenotypes. As we continue to unravel the microbial dimensions of mental health, these findings remind us that the boundaries between microbiology and brain science are increasingly blurred, with profound implications for human wellbeing.

Subject of Research:
Mechanism by which Staphylococcus aureus nasal colonization influences host sex hormone metabolism and induces depressive-like behavior in mice.

Article Title:
Nasal Staphylococcus aureus carriage promotes depressive behaviour in mice via sex hormone degradation.

Article References:
Xiang, G., Wang, Y., Ni, K. et al. Nasal Staphylococcus aureus carriage promotes depressive behaviour in mice via sex hormone degradation. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02120-6

Schizophrenia has long been enigmatic regarding its etiology, with genetic, environmental, and neurochemical factors implicated, yet no definitive biological markers identified. This investigation offers a novel perspective, suggesting that disruptions in the body’s microbiota, spanning multiple microbial kingdoms, might not only accompany but potentially influence disease pathogenesis and symptomatic manifestations. The findings have profound implications for biomarker development and personalized medical interventions targeting microbial ecosystems.

The researchers collected and analyzed samples from a cohort of diagnosed schizophrenia patients alongside matched healthy controls, employing comprehensive shotgun metagenomic sequencing to capture a broad snapshot of microbial DNA. Importantly, the team extended their scope beyond bacteria—often the sole focus of microbiome studies—to incorporate fungal and viral populations, reflecting a more holistic ecosystem view. This approach marks a significant methodological advance, acknowledging that the human microbiome’s stability and homeostasis depend on interplay between diverse microbial kingdoms.

Results revealed a striking reconfiguration of microbial communities in patients with schizophrenia. Specifically, bacterial taxa known for neurotransmitter metabolism, immune interaction, and gut-brain axis communication showed notable depletion, while certain pathogenic or opportunistic organisms across all kingdoms were significantly enriched. The fungal changes included an overrepresentation of Candida species, known to modulate immune responses and influence the gut mucosal barrier. Viral elements, especially bacteriophages that infect key bacterial populations, appeared disordered, suggesting a cascading effect that destabilizes microbial network function.

One of the most fascinating aspects of the study was the statistical correlation established between microbial shifts and key clinical variables such as symptom severity, cognitive impairment, and treatment responsiveness. The multi-kingdom microbial profiles were predictive of specific symptom clusters, highlighting potential mechanistic links. For example, reductions in butyrate-producing bacteria aligned with exacerbated negative symptoms, underscoring the microbial metabolite’s essential neuroprotective role. Meanwhile, altered fungal populations correlated with systemic inflammation markers, implying immune dysregulation pathways involvement.

This research supports the emerging hypothesis that dysbiosis—an imbalance in microbiota composition—may contribute causally to psychiatric illness, rather than being a mere epiphenomenon. The involvement of fungal and viral constituents complicates this landscape, advocating for integrated microbiome analyses in neuropsychiatric research. Furthermore, the dynamic nature of bacteriophage populations introduces a novel regulatory layer influencing bacterial community structure and function, potentially affecting gut-brain communication routes and host neuroimmune signaling.

From a mechanistic standpoint, the study posits that the multi-kingdom microbial disruptions may perturb metabolic pathways central to neurotransmitter synthesis, barrier integrity, and immune modulation. Altered microbial enzymatic activities could shift tryptophan metabolism toward neurotoxic metabolites, exacerbating oxidative stress and neuronal dysfunction characteristic of schizophrenia. Likewise, fungal overgrowth might stimulate chronic low-grade inflammation, compromising blood-brain barrier permeability and facilitating neuroinflammation.

Clinically, these insights pave the way for innovative diagnostic and therapeutic strategies. Microbial signatures identified could serve as non-invasive biomarkers for disease staging, prognosis, or treatment monitoring. Beyond that, manipulation of the microbiota through probiotics, prebiotics, antifungal agents, or phage therapy offers a tantalizing avenue for adjunctive schizophrenia treatment. The multi-kingdom perspective underscores the need to consider interactions across microbial domains when designing such interventions to avoid unintended ecological imbalances.

The methodological rigor of this study deserves special attention. The research team employed state-of-the-art bioinformatics pipelines capable of resolving complex microbial taxonomies and functional potentials from metagenomic data, overcoming the classical challenges of fungal and viral detection. Statistical models controlled for confounders such as medication use, diet, and comorbidities, bolstering the robustness of observed associations. These advances in multi-omics integration set a new standard for microbiome research in psychiatric disorders.

Moreover, the temporal aspect of microbial dynamics in schizophrenia remains an exciting question inspired by these findings. While this cross-sectional study elucidates associations, longitudinal investigations could examine whether microbial changes precede symptom onset or evolve with disease course and treatment. The prospect that microbial ecosystem modulation could delay or mitigate schizophrenia progression is profoundly compelling and warrants urgent exploration.

Adding another layer of complexity, the study hints at the influence of host genetics on shaping multi-kingdom microbiota composition. Given that schizophrenia has a significant heritable component, interactions between host genotype and microbial ecology might underlie susceptibility patterns and phenotypic variability. Future research integrating genomic, microbiomic, and clinical data will be essential to decipher these multifaceted relationships.

The ramifications of this investigation extend beyond schizophrenia. The approach and findings exemplify a paradigm shift in neuropsychiatric research, emphasizing the gut-brain-microbiota axis’s integral role and drawing attention to the previously underappreciated contributions of fungi and viruses. These insights open fertile ground for addressing other mental health conditions with suspected microbiome links, including depression, bipolar disorder, and autism spectrum disorders, via multi-kingdom microbial profiling.

In sum, this landmark study by Zhu, Liang, Chen, and colleagues illuminates the complex microbial tapestry entwined with schizophrenia’s clinical landscape. By unveiling profound multi-kingdom microbial rearrangements intimately tied to symptomatology and disease markers, it challenges existing dogmas and enriches our understanding of psychiatric illnesses through a microbial lens. The path now leads toward harnessing these discoveries to revolutionize diagnosis, treatment, and ultimately improve patient outcomes.

As researchers continue to decode the human microbiome’s secrets, this work stands as a beacon highlighting the necessity of embracing biological complexity to tackle diseases that have thus far eluded definitive cures. It underscores the transformative potential of integrating microbial ecology with neuropsychiatry and encourages the scientific community to venture beyond bacteria-centric views to embrace the full spectrum of microbial life influencing human health.

Subject of Research: Multi-kingdom microbial alterations and their relationships with clinical characteristics in schizophrenia patients

Article Title: Multi-kingdom microbial changes and their associations with the clinical characteristics in schizophrenia patients

Article References:
Zhu, B., Liang, L., Chen, S. et al. Multi-kingdom microbial changes and their associations with the clinical characteristics in schizophrenia patients. Transl Psychiatry 15, 228 (2025). https://doi.org/10.1038/s41398-025-03449-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03449-6